Bob Roche
Analyst · Oppenheimer
Thanks, Chris. As Chris mentioned earlier, we had a very solid second quarter. I'm especially pleased about the margin expansion of CCM, CIT coming-off market lows and position to deliver sequential growth in the next few quarters. CFTs order book improving our disciplined approach to capital deployment in the form of share repurchases and dividends continued investment in our high ROIC businesses to drive organic growth. And our portfolio optimization actions including the vesting CBF and the announced agreement to acquire Henry Company. Please turn the revenue bridge on Slide 8 of the presentation. Revenue was up 22% in the second quarter driven by CCM and CFT offset by the well documented commercial aerospace declines at CIT. Organic revenue was up 20.7%. CCM and CFT each delivered greater than 25% organic growth in the quarter. Acquisitions contributed 0.4% of sales growth for the quarter and FX was a 90 basis point tailwind. On Slide 9, we have provided and adjusted EPS where you can see second quarter adjusted EPS was $2.16 which compares with $1.95 last year. Volume price and mix combined were $1.30 year-over-year increase. Raw material, freight and labor costs were $0.95 headwind. Interest in tax together were a $0.01 headwind. Share repurchases contributed $0.07 and COS contributed additional $0.12. Higher OpEx was a $0.32 headwind year-over-year half of which is related to the May vesting and cash settlement of stock appreciation rights granted to all Carlisle employees outside of the U.S. in 2018, with the remainder reflecting the resumption of more normalized expense level versus last year's cost containment measures taken in the depths of the pandemic. Now let's turn to Slide 10 on the second quarter performance by segment in more detail. At CCM, the team again delivered outstanding results with revenues increasing 27.5% driven by volume and price along with 70 basis points of foreign currency translation tailwind. All of CCMs product lines deliver 20% growth with particular strength and architectural models and spray foam insulation. CCM effectively managed raw material inflation headwinds experienced in the quarter with discipline pricing for active sourcing and allocating products to strategic customers. Adjusted EBITDA margin at CCM was 21.5% in the second quarter, a 60 basis point decline from last year driven by higher raw material prices partially offset by volumes price and COS savings. Despite raw materials being a headwind in second quarter, we continue to anticipate, net neutral price raw’s for the full year. Adjusted EBITDA grew 24% to $201.2 million again demonstrating the earnings power of our CCM business. Please turn to Slide 11, CIT results. CIT revenue declined 8.2% in the second quarter. As has been well publicized, this decline was driven by the pandemics continued impact on commercial aerospace markets. We still anticipate a prolonged recovery in aerospace but are optimistic there will be resumption and growth as we enter the second half of the year. CIT’s medical platform continues to build a robust pipeline of projects with an increasing backlog. We continue to expect sequential improvement from pent-up demand as the impacts of COVID on hospital CapEx and postponed elective surgeries ease. CIT’s adjusted EBITDA margins decline year-over-year to 8%, driven by commercial aerospace volumes, partially offset by price COS and lower expenses. Given the positive indicators, we are optimistic that CIT will deliver sequentially improving financial performance into the second half of 2021. Turning now to Slide 12. CFT sales grew 54% year-over-year, organic revenue improved 44.3% and acquisitions added 3.6% in the quarter, FX contributed 6%. CFT is well positioned accelerate through the recovery due to continued stabilization in key end markets driven by an improved industrial capital spending outlook in 2021 coupled with new product introductions, would have included $4.1 million of incremental new product sales in 2021 year-to-date, along with our continued pricing result. Adjusted EBITDA margins of 15.9% or over 100 basis point improvement from last year. This improvement primarily affects volume pricing and mix. On Slide 13 and 14, we show selected balance sheet metrics. our balance sheet remains strong. We ended the quarter with $713 million of cash on hand and $1 billion of availability under our revolving credit facility. We continue to approach capital deployment in a balanced and disciplined manner, investing in organic growth through capital expenditures and opportunistically purchasing shares, while also actively seeking strategic and synergistic acquisitions. In the quarter, we repurchased 643,000 shares for $116 million bringing our 2021 year-to-date total to 1.6 million shares for $266 million. We paid $28 million of dividends in the second quarter bringing our ‘21 total to $56 million. We invested $32 million of CapEx into our high returning businesses to drive organic growth bringing our 2021 total to $55 million. A few examples of these investments include our new Missouri polyiso facility, expansion of our TPO line in Carlisle PA and investment in our spray foam capabilities in Cartersville, Georgia. In addition, and as has been noted, we announced an agreement to purchase Henry Company for $1.575 billion. Henry generated revenue a $511 million and adjusted EBITDA $119 million representing a 23% EBITDA. Additionally, Henry expected to deliver $100 million of free cash flow in our first year of ownership. We also expect meaningful cost synergies of $30 million by 2025. Finally, we expect Henry to be immediately accretive to Carlisle’s EBITDA margin adding over $1.25 of adjusted EPS in 2022. Free cash flow for the quarter was $64.6 million a 54% decline year-over-year due to increased working capital usage related to our high sales growth of 22%. Turning to Slide 15, you can see the outlook for 2021 and corporate items. Corporate expenses now expected to be approximately $125 million up from the previous estimate of 120. The increase is wholly related to the vesting in cash settlement of our stock appreciation rights discussed earlier. We expect depreciation and amortization expense to be approximately $210 million. We still expect free cash flow conversion of approximately 120%. For the full year, we continue to invest in our business and expect capital expenditures approximately $150 million. Net interest expense is still expected to be approximately $75 million for the year. And we still expect our tax rate to be approximately 25%. Finally, restructuring is expected in 2021 to be approximately $20 million. And with that, I'll turn the call back over to Chris.